Table 2 |
||||
|
Supplementation impact on malaria and general morbidity |
||||
|
Placebo |
Supplemented |
RR (95% CI) |
p-value |
|
|
|
||||
|
Number of fever episodes (mean ± SD) |
2.04 ± 1.2 |
1.63 ± 1.2 |
- |
0.038 |
|
Number of malaria episodes (mean ± SD) |
1.5 ± 1.005 |
1 ± 0.93 |
- |
0.029 |
|
P*PFever episodes |
153 |
119 |
1.28 (1.09–2.94) |
0.030 |
|
P*PMalaria episodes |
106 |
74 |
1.43 (1.10–2.40) |
0.025 |
|
Free of pathologies |
17% (9–25) |
31% (16–46) |
- |
0.05 |
|
Cough episodes |
51,3 (40–62.6) |
45,9% (34.6–57.2) |
- |
0.510 |
|
Diarrhea episodes |
52,7% (41.4–64) |
28,3% (18.1–38.5) |
- |
0.002 |
|
Geometric mean density P falciparum (asexual forms/μl) |
10672 (7589–15007) |
7704 (5409–10971) |
- |
0.049 |
|
|
||||
|
P*PNumber of episodes Mean ± SD or % (CI 95%) Child-years was 37 in each group |
||||
|
Zeba et al. Nutrition Journal 2008 7:7 doi:10.1186/1475-2891-7-7 |
||||
